A Prospective Study of Clinical Outcomes Following a Single Intradiscal Injection of Bone Marrow Aspirate Concentrate (BMAC) for Single Level Discogenic Low Back Pain

Inclusion Criteria: * Ages 18 to 60 years * Symptomatic discogenic low back pain, clinically demonstrated by a loss of lumbar range of motion and pain to deep palpation over the symptomatic disc. * MRI confirmed single level lumbar disc height loss \<50% (Modified Pfirrman grade \<=7). * MRI confirmed isolated lumbar disc degeneration OR o If zygapophysial joint degeneration is present on MRI, subject must have failed intra-articular injection or medial branch block (\<50% pain relief) to be eligible for enrollment. PI will have final discretion as to whether the patient's symptoms originate from a single disc. * Patient must have completed at least 3 months conservative treatment. Conservative treatment may include NSAIDs or Acetaminophen when medically appropriate and physiotherapy, chiropractic care, or a guided home exercise program. * BMI \< 40 * Back pain greater than leg pain with back pain rating on a 100 mm visual analog scale (VAS) \>= 40 mm * Pain Catastrophizing Scale \<= 30 Exclusion Criteria: * Prior fusion at the level to be treated * \>2 levels requiring intervention * Non discogenic source of back pain * Intradural disc herniation * Full thickness annular tear at the index level. * Lumbar spine surgery within the past 6 months. * Pregnant or breastfeeding. * Known allergy or sensitivity to heparin or citrate (used for processing BMAC) * Coagulopathy preventing spinal injection * Active infection * Malignancy within past 5 years other than basal cell or squamous cell skin cancer. * Severe uncontrolled medical condition * Other significant pain generator that may affect the subject's answers to PRO questionnaires. * Current Tobacco use * Pending litigation involving subject's back pain * Incarcerated at the time of study enrollment * Inability to give informed consent for study participation for any reason